Objective Metabolites and somatic mutations involved in the EGFR-TKI efficacy remains unclear in the first-line non-small cell lung cancer(NSCLC)patients with EGFR sensitizing mutation.Here we performed a joint analysis of metabolomics and genomics data to identify metabolites and somatic mutations as biomarkers for the efficacy of first-line EGFR-TKI therapy.